Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. AKBA

Healthcare  —  Drug Manufacturers Specialty & Generic
0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

 0.00 0.00 0.00 0.00
P/S ratio 3.21 1.75 1.60 1.40
P/FCF ratio 22.35 6.10 6.18 7.63
P/Operating CF 25.72 13.30 (17.50) 87.19
P/B ratio 17.38 12.70 13.56 12.29
Price to Tangible BV 0.00 0.00 0.00 0.00
EV/Sales 2.76 1.25 1.11 0.92
EV/EBITDA 22.17 11.91 39.17 0.00
EV/Operating CF 19.19 4.34 4.26 4.85
EV/FCF 19.22 4.35 4.29 5.00
Quick Ratio 1.74 1.42 1.30 1.30
Current Ratio 1.94 1.55 1.40 1.43
Net Debt/EBITDA (24.92) 16.59 26.04 18.46
Debt/Assets 13.08% 12.81% 13.49% 14.17%
Debt/Equity 1.15 1.48 1.79 1.98
Asset Turnover 0.79 0.79 0.69 0.63
Operating CF/Net income 52.05 (2.54) 2.34 (0.40)
Capex/Depreciation (0.24) (0.22) (0.19) (1.84)
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 25.43% 46.25% 27.65% 28.62%
Selling, General and Administrative Expense of Revenue 49.51% 45.28% 56.84% 57.34%
Intangible Assets out of Total Assets 0.16 0.16 0.16 0.17
Share Based Compensation of Revenue 5.48% 5.55% 6.85% 6.57%
Graham Net Nets (0.09) (0.22) (0.25) (0.31)
Graham Number 0.00 0.00 0.00 0.00
Earnings Yield (2.46%) (1.06%) (5.55%) (9.47%)
Free Cash Flow Yield 4.47% 16.39% 16.17% 13.10%
Revenue per Share 0.22 0.22 0.20 0.18
Operating CF per Share 0.11 0.12 (0.08) 0.01
Capex per Share 0.00 0.00 0.00 0.00
Free Cash Flow per Share 0.11 0.12 (0.08) 0.01
Cash per Share 0.63 0.72 0.61 0.58
Shareholders Equity per Share 0.16 0.13 0.10 0.09
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 0.16 0.13 0.10 0.09
Free Cash Flow 28.03 31.06 (21.27) 2.45
Working Capital 124.96 90.02 69.60 68.69
Capital Expenditures (0.08) (0.07) (0.06) (1.08)
Net Current Asset Value (64.22) (91.00) (91.66) (95.09)
EV/EBIT 35.03 12.55 48.67 0.00
Capex to Sales 0.00 0.00 0.00 0.02
Net Profit Margin 0.92% (21.25%) (16.91%) (18.13%)
Price to Operating Income 40.73 17.62 70.18 0.00
Other line items
Average Receivables 49.20 40.70 62.04 63.16
Average Payables 11.79 18.18 10.52 10.49
Average Inventory 19.57 15.93 16.36 14.86
Average Assets 285.65 298.62 336.35 347.63
Average Common Equity (4.41) (8.29) 25.98 27.12

Fold the line items

Columns are period end dates